Publicaciones en colaboración con investigadores/as de Complejo Asistencial de Segovia (4)

2023

  1. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

    Viruses, Vol. 15, Núm. 2

  2. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

    Viruses, Vol. 15, Núm. 4

2022

  1. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092